Thomas Rose and Heather Morehouse Ettinger

Thomas Rose is an exceptionally experienced attorney who concentrates his practice on U.S. cross-border securities, corporate law matters, and life science issuers. With a particular focus on U.S.-Canada activity, every year he and his team advise clients with respect to financing transactions totaling billions of dollars – regularly landing them among the top performers on Thomson Reuters' annual league tables and recently earning the "Pharmaceutical Deal of the Year" Atlas Award from Global M&A Network. Tom counsels U.S. and foreign issuers in connection with initial listings on the New York Stock Exchange (NYSE), the NYSE MKT and the Nasdaq Stock Market (NASDAQ). He also helps clients ensure compliance with ongoing U.S. reporting and corporate governance requirements under U.S. federal securities laws and exchange rules, and acts as a principal American liaison (PAL) on the over-the-counter (OTC) international markets.

Heather Morehouse Ettinger, Ph.D counsels life sciences clients on a variety of intellectual property matters. She excels at due diligence studies, loss of exclusivity analyses, and agreement drafting in connection with buy- and sell-side transactions and collaborations for her clients, which range from preclinical biotechnology companies to large clinical pharmaceutical companies. Heather regularly advises on Hatch-Waxman issues, biosimilars strategy, and litigation and post-grant proceedings, such as inter partes reviews. She also manages the worldwide prosecution of numerous life sciences patent portfolios. Heather routinely works with the firm's corporate team to counsel international corporations in preparing their intellectual property portfolios for U.S. cross-border securities transactions. Heather is a registered patent attorney with the U.S. Patent and Trademark Office. In addition to earning her J.D., Heather has a Ph.D. in biological and biomedical sciences and a B.S. in biology.